Navigation Links
Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant Under the U.S. Patient Protection and Affordable Care Act of 2010
Date:11/2/2010

CHARLESTON, S.C., Nov. 2, 2010 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today that it was awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program.  Charleston Laboratories received the maximum individual grant award to advance the development of its lead product, CL-108, for moderate to severe pain. CL-108 is currently being prepared for evaluation in an 1,100-patient Phase III clinical trial at investigative sites throughout the US, including major research universities in the US.

The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. The QTDP program was created by Congress on May 21, 2010 under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act (PPACA).  

"Charleston is honored by this award," said Mr. Paul Bosse, Charleston Labs' CEO. "Receiving this grant acknowledges the potential of our company and, importantly, the clinical and economic benefits that our different opioid products can provide patients with debilitating pain."  

About Charleston Laboratories, Inc.

Charleston Laboratories Inc., headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mobile Tour to Provide Prescription Help to the Uninsured in Charleston, S.C.
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2011
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status
4. Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of Eddie Munson to Board of Directors
6. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
7. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
8. Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax®
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets
11. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Newly published research from the CVS Health (NYSE: ... private retailer can play in restricting access to tobacco ... in the American Journal of Public Health , ... all CVS Pharmacy stores reduced the number of cigarette ... impact on those who bought cigarettes exclusively at CVS ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... pain, announced that Vincent J. Angotti ... member of the company,s board of directors, effective ... two decades of experience leading executive and commercial ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications provided ... visit are necessary for long-term opioid use to take ... 16 th edition of The New England ... physicians see more patients in acute pain than in ... , MD, FACEP, president of the American College of ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a national staffing ... named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , ... notable contributions to the staffing industry over the last twelve months. Industry insiders ...
(Date:2/17/2017)... CO (PRWEB) , ... February 17, 2017 , ... Top ... annual International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, ... Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 ...
(Date:2/16/2017)... York, New York (PRWEB) , ... February 17, ... ... work and determination. After what took over 10 years of research, development and ... technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ingredients ...
(Date:2/16/2017)... ... February 17, 2017 , ... The Price Agency, a ... and entrepreneurs in the Birmingham area, is announcing an ongoing charity event to ... her medically challenged son, Anius. , Anius is medically complex with diagnoses consisting ...
Breaking Medicine News(10 mins):